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Abstract 
The cationic peptide, salmon calcitonin (sCT) was complexed with the cationic amphiphilic 
polyelectrolyte, poly(allyl)amine, grafted with palmitoyl and quaternary ammonium moieties at 
pH 5.0 and 7.4 to yield particulates (sCT-QPa). The complexes were approximately 200nm in 
diameter, had zeta potentials ranging from +20 to +50mV, and had narrow polydispersity indices 
(PDIs).  Differential scanning calorimeter revealed the presence of an interaction between sCT 
and QPa in the complexes. Electron microscopy confirmed the zeta-size data and revealed a 
vesicular bilayer structure with an aqueous core. Tyrosine- and Nile red fluorescence indicated 
that the complexes retained gross physical stability for up to 7 days, but that the pH 5.0 
complexes were more stable.  The complexes were more resistant to peptidases, serum and liver 
homogenates compared to free sCT.  In vitro bioactivity was measured by cAMP production in 
T47D cells and the complexes had EC50 values in the nM range. While free sCT was unable to 
generate cAMP following storage for 7 days, the complexes retained approximately 33% 
activity.  When the complexes were injected intravenously to rats, free and complexed sCT (pH 
5.0 and 7.4) but not QPa reduced serum calcium over 120 min.  Free and complexed-sCT but not 
QPa also reduced serum calcium over 240 min following intra-jejunal administration.     In 
conclusion, sCT-QPa nanocomplexes have been synthesised that are stable, bioactive and 
resistant to a range of peptidases.  These enhanced features suggest that they may have the 
potential for improved efficacy when formulated for injected and oral delivery.     
 
Key words: 
Salmon calcitonin, poly(allyl)amine, amphiphilic polymers, oral peptide delivery, peptidase 
inhibition. 
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1. Introduction 
 Since complexation of bovine serum albumen (BSA) with a synthetic polyelectrolyte was 
first described [1], such complexes have been used widely in the food and biotechnology 
industry.  Examples include stabilisation of enzymes for biosensors [2], and for developing 
protein separation methods [3]. Use of polyelectrolytes for non-injected peptide and protein 
delivery resulted in formulation of positively-charged chitosan nanocomplexes or hydrogels with 
insulin [4, 5], BSA [6], and catalase [7]. The principle mechanism of the non-covalent 
association is based on electrostatic interaction between positively-charged polymers and 
negatively-charged proteins to yield a polyelectrolyte complex. Most peptides and proteins 
however, typically exhibit amphiphilic character due to the presence of multiple hydrophobic 
and hydrophilic amino acid residues in the primary sequence. Amphiphilic polymers may have 
unique potential in peptide delivery due to their ability to interact with such peptides via both 
electrostatic and hydrophobic association. However, to our knowledge only a few groups have 
studied them for delivery of therapeutic peptides including insulin [8] and salmon calcitonin 
(sCT) [9].  
Our previous work demonstrated the use of novel comb-shaped amphiphilic 
polyelectrolytes based on polyallylamine (PAA) designed for oral delivery of insulin [10-12]. 
PAA protected insulin from in vitro gastrointestinal enzymatic degradation by pepsin, and 
trypsin to an extent [12], due to the nature of the hydrophobic pendant group and the presence of 
quaternary ammonium moieties [10]. Among the amphiphilic polyelectrolytes examined, the 
most promising analogue was PAA grafted with a combination of palmitoyl (4.2% mole) and 
quaternary ammonium moieties (QPa, 73% mole). Proteins and peptides can be anionic or 
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cationic at physiological pH, depending on their isoelectric point (PI) and the pH of the 
compartment solution. Therefore, it is important to assess the ability of amphiphilic 
polyelectrolytes to deliver both cationic and anionic peptides. To date, most research has 
focussed on complexation between polymers and peptides of opposite charge. There are reports 
which suggest that polyelectrolyte complexation can indeed be formed with the same overall 
charge due to the presence of localized patches of opposite charge on the peptide surface [13], or 
due to hydrophobic interactions or hydrogen bonding between polymer and peptide [14].  
The question for this current study was therefore whether PAA could be complexed with 
a cationic peptide while retaining physicochemical properties that are compatible with 
maintenance of bioactivity.  sCT is a 32-residue calcium-regulating peptide hormone produced 
by parafollicular cells of the thyroid gland, which is used clinically as an adjunct anti-resorptive 
treatment for post-menopausal osteoporosis and also as a second line treatment for Paget disease 
[15]. Recent data suggests that sCT also has potential as a disease-modifying anabolic agent 
acting on osteoarthritic cartilage to promote collagen and preteoglycan synthesis [16]. Marketed 
sCT for osteoporosis is available as a nasal spray or as subcutaneous/intramuscular injections. 
An oral product would have patient acceptability advantages over both nasal sCT and oral 
bisphosphonates, the former prone to occasional local mild irritation due to the presence of 
permeation enhancers [17], while the latter elicits a range of intestinal side-effects in a cohort of 
patients [18].    Anionic sodium tripolyphosphate was recently complexed to sCT to form an 
ionic complex via electrostatic attraction and it had some oral efficacy in rats [19].  Here, 
complexation between the cationic QPa and cationic sCT was achieved in pH 5.0 and pH 7.4 
buffers and the resulting nanocomplexes yielded positive outcomes from the standpoint of 
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physicochemical properties, resistance to enzymatic degradation, in vitro sCT bioactivity as well 
as in vivo hypocalcaemic efficacy in rats.  
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2. Materials and Methods 
 
2.1. Materials 
Poly(allylamine hydrochloride) (PAA) (Mw = 15 kDa), palmitic acid-N-
hydroxysuccinimide ester (98%), sodium acetate, tris(hydroxymethyl) aminomethane (Tris) 
(≥99%) and Nile Red were all purchased from Sigma–Aldrich, UK. All solvents (HPLC grade) 
and glacial acetic acid were purchased from Fisher Scientific Chemicals, UK. sCT was 
purchased from PolyPeptide Laboratories (Denmark). The Parameter™ cAMP (EIA) kit was 
purchased from R&D systems, UK. Tissue culture reagents were obtained from BioSciences, 
Ireland. All other chemicals were of reagent grade. T47D cells were purchased from LGC 
Standards, UK. 
 
2.2. Synthesis of QPa 
In accordance with [10], PAA was reacted with palmitic acid-N-hydroxysuccinimide 
ester, based on molar feeds of 1:0.025 (PAA monomer: palmitoyl group) to obtain PAA grafted 
with palmitoyl-pendant groups (Pa). Quaternisation (Q) was carried out by reacting Pa with over 
a 1000 molar excess of methyl iodide to obtain quaternary ammonium compounds, QPa (Fig. 1). 
The novel amphiphilic polymers were characterised by elemental analysis and 1H NMR and the 
results confirmed 4.2% mole palmitoylation and the palmotoyl graft [10, 11]. 
 
2.3. Preparation of sCT-QPa nanocomplexes 
Complex preparation of sCT with QPa was carried out similar to our previous method 
using insulin [11]. Two buffers, Tris (pH 7.4) and acetate buffer (pH 5.0) were used to separately 
prepare sCT-QPa complexes. Tris buffer was made up of 0.1 M Tris: 0.01 M HCl (87:13 % 
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(v/v)), and the acetate buffer was composed of sodium acetate (0.871 gL−1) and glacial acetic 
acid (0.216 gL−1). Solutions (4 mgmL−1) were prepared by sonicating the polymer in either 
buffer using a Soniprep 150® sonicator (MSE Ltd., UK) for 5 min at the maximum amplitude.  
sCT stock solutions (2 mgmL−1) were prepared also in both buffers using gentle magnetic 
stirring. Equal volumes (2 mL each) of QPa and sCT solutions were added together and the sCT-
QPa complexes were formed spontaneously after mixing. The solutions were then left at room 
temperature for 120 min and the pH values were re-checked before characterisation as described 
in Section 2.4 and 2.5.  
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Fig. 1. Chemical structure of quaternary ammonium palmitoyl polyallylamine (QPa).   
 
2.4. Characterization of polymer, sCT complexes 
2.4.1. Differential scanning calorimetry (DSC) 
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QPa, sCT and QPa-sCT complexes (2:1 mgmL−1) were freeze dried in a VirTis adVantage freeze 
drier (Biopharma Process Systems, UK) in both Tris and acetate buffers. Samples (1-2 mg) were 
then heated from 0oC to 300oC at 20oCmin-1 in a Q100 differential scanning calorimeter (TA 
instruments, UK), precalibrated with indium. The above experiment was repeated using sCT as 
received from the supplier. 
2.4.2. UV Absorbance  
The turbidity of QPa, sCT and sCT-QPa complexes were tested at day 0, 1 and 7 after 
preparation by taking absorbance readings at 350 nm using a Biomate 5 UV spectrophotometer 
(Thermo Spectronic, England) with a 1 cm quartz cuvette. Absorbance values were determined 
after blanking the spectrophotometer with the buffer used to prepare sCT/QPa samples. The 
samples were maintained at room temperature in the dark over the 7 days. 
 
2.4.3. Intrinsic tyrosine fluorescence 
The fluorescence of the tyrosine residues within sCT was measured using a LS 55 
luminescence spectrometer (Perkin Elmer, USA) according to [20]. The changes of the emission 
spectra of the intrinsic tyrosine residues within the sCT give an indication of the physical 
stability of sCT. Emission spectra were recorded using the supplied software over an emission 
wavelength range of 290 to 400 nm after excitation at 274 nm using slit widths of 3 nm. An 
average of three scans was taken for each sample. Intensity values at peak emission wavelength 
were noted at days 0, 1 and 7 after the formation of sCT-QPa complexes and compared to free 
sCT. 
 
2.4.4. Nile red fluorescence 
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Since intrinsic tyrosine fluorescence measurement may be less sensitive in detecting sCT 
aggregation compared to extrinsic fluorescence, extrinsic Nile red fluorescence was also used to 
determine sCT stability.  QPa, sCT and sCT-QPa complexes were spiked with a 0.10 mM 
solution of Nile Red in ethanol (40 µL in 4 mL, n=3) [20]. Controls consisting of each buffer 
(4mL) were also spiked with Nile red. All samples were left in the dark at room temperature for 
the duration of the study.  The emission intensities of the Nile red-spiked samples and nile red 
alone in each buffer were recorded between wavelengths of 600-700nm following initial 
excitation at 575 nm at a slit width of 7.5 nm. Peak intensities were measured using a LS 55 
luminescence spectrometer (Perkin Elmer, USA) at days 0, 1 and 7 after sample preparation with 
an average of three scans of each sample. 
2.4.5. Particle size analysis: photon correlation spectroscopy (PCS) 
Hydrodynamic diameters and polydispersity indices (PDI) of polymer, sCT and sCT-QPa 
complexes in both buffers were determined using photon correlation spectroscopy (PCS) 
(Zetasizer Nano-ZS, Malvern Instruments, UK) at 25 °C. Analysis was carried out at days 0, 1 
and 7 after preparation. 
 
2.4.6. Zeta potentials 
The zeta potential of QPa, sCT and sCT-QPa complexes were analysed using PCS (Zetasizer 
Nano-ZS, Malvern Instruments, UK) at days 0 and 7 after preparation. Prior to measurement, -50mV 
standards (Malvern Instruments, UK) were analysed; the data obtained agreed with that stated by the 
manufacturer. 
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2.4.7 Transmission electron microscopy (TEM) 
Formvar/carbon-coated 200 mesh copper grids were glow-discharged and freshly-
prepared complex solutions were dried to form a thin layer onto the hydrophilic support film. 1% 
aqueous methylamine vanadate (Nanovan®; Nanoprobes, Stony Brook, NY, USA) stain was 
applied and the mixture air-dried. The negatively-stained complexes were imaged with a LEO 
912 energy filtering transmission electron microscope, at 80 or 100 kV.  
 
2.5. In vitro and in vivo characterisation of sCT-QPa  complexes 
2.5.1. In vitro bioactivity: Intracellular cAMP elevation by sCT and complexes in T47D cells 
cAMP-secreting activities of sCT and complexes were assessed using a T47D (human 
breast cancer cells) in vitro bioassay [21]. Human breast cancer cells (T47D) cells over-expresses 
calcitonin receptors and resulting in intracellular cAMP release upon activation by sCT. T47D 
cells were maintained in RPMI-1640 culture medium (Gibco) containing 1% penicillin–
streptomycin (Gibco), 10% fetal bovine serum (Gibco) and insulin (0.2 IU/ml). The cells were 
plated at an initial density of 1.0 × 105 cells/well and incubated in a 95% air: 5% CO2 
atmosphere at 37 °C for 24 hours. Media was replaced with serum-free media and incubated for 
a further 24 hours. After washing with Hank's balanced salt solution (HBSS) (Sigma), cells were 
pre-incubated with the serum free media, supplemented with 0.2 mM 3-isobutyl-1-methyl-
xanthine (IBMX) at 37 °C for 120 min. The cells were then incubated with different 
concentrations of freshly prepared (day 0) sCT and sCT-QPa (pH 5.0 and 7.4) complexes at 37 
°C for 15 min. After removing the supernatants, intracellular cAMP was extracted from the cells 
by lysis and measured by ELISA (R&D Systems, UK). Concentration-response curves were also 
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carried out on samples from the same stocks after 7 days (day 7).  The concentrations of sCT in 
the complexes were directly comparable with free sCT.  
2.5.2. Intestinal enzyme metabolism 
sCT-QP complexes were incubated with intestinal enzymes in transport buffer according 
to our previous description [22]: TPCK (N-p-tosyl-Lphenylalanine chloromethyl ketone)-treated 
trypsin (0.5 μM), TLCK (1- chloro-3-tosylamido-7-amino-2-heptanone)-treated chymotrypsin 
(0.1 μM) and elastase (0.48 μM). The concentrations of enzymes used were similar to those 
present in the gastrointestinal tract.  Enzymes and substrates were incubated separately at 37 °C 
for 15 min, followed by co-incubation for 0, 15, 30, 45, 60 and 90 min. Samples were analysed 
for the capacity to induce cAMP production in T47D cells. Rate constants and half lives for 
formulations were calculated by assuming first order kinetics. 
 
2.5.3 Hypocalcaemia of sCT-QPa formulations in rats: intravenous and intra-jejunal 
administration 
Fasted male Wistar rats (300-350g) were initially anesthetised using intra-peritoneal (i.p.) 
injection of ketamine (75 mg/kg) and xylazine (10 mg/kg). Anaesthesia was maintained with 
isoflurane gas at the rate of 1.5 L/min mixed with O2 (1 L/min) through a gas mask.  
Rats were randomly divided into groups and were injected via the tail vein with 40 µg/kg (200 
IU/mL/kg) sCT from each formulation: sCT, QPa, sCT-QPa, each prepared at both pH 5.0 and 
7.4. Serum samples were obtained directly from the heart at time 0 and then at 15, 30, 60 and 
120 min after i.v. injection. Intra-jejunal (i.j.) administration was also carried out in separate 
studies based on previous methods [23].  The proximal jejunum from anaesthetised rats were 
exposed after a midline laparotomy. 15 cm of jejunum was isolated by tighten the extremities up 
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with silk, taking care to avoid damage to blood vessels. Solutions containing 0.1mg/ml sCT (500 
IU/ml) at the volume of 1ml/300g of bodyweight were instilled into the surgically exposed 
jejunal segments. The i.j. study had same design as for intravenous (i.v.) study, except that 
samples were withdrawn up to 240 min.  Serum samples were analysed for calcium using a 
Randox Laboratory clinical chemistry colorimetric analyzer at a wavelength of 612 nm [22].  
Animal experimental procedures adhered to the Principles of the Laboratory Animal Care, were 
performed in compliance with the Irish Department of Health and Children animal licence 
number, B100/4193, and were approved by the UCD Animal Research Ethics Sub-Committee.  
 
2.6. Statistical analysis 
R Statistical Language was used to perform non-linear regression, t-tests, Tukey-HSD 
post hoc ANOVA comparison and to construct confidence intervals. P < 0.05 was designated as 
the level of significance. 
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3. Results 
3.1 Characterisation of sCT-QPa complexes 
3.1.1. DSC 
From the acetate samples, complexation led to a change in the DSC profile compared to 
free sCT and QPa alone. Free sCT had two endotherms, a broad endotherm at 70°C and another 
sharp endotherm at 130°C while QPa had endotherms at 90 and 240°C (Fig 2A). Upon 
complexation, the endotherms observed for free sCT had disappeared and a broad thermogram 
occurring at 120°C was observed. This result is consistent with our findings with the QPa-insulin 
complexes and other polyelectrolyte complexes [11,19]. The physical-chemical interaction 
between sCT and QPa had resulted in the disappearance of free sCT endotherms and the shift of 
QPa endotherm to a higher temperature.  
In regards the Tris samples, the picture is more complex. QPa and the complex thermal 
profiles seemed to be very similar in acetate buffer, but not so in Tris. There was a large 
endotherm at 150oC in the QPa Tris buffer sample that was not present in the acetate buffer 
sample, which may be due to the Tris itself having recrystallised on freeze drying (Fig 2B).  The 
absence of this large peak in the thermal profile of QPa freeze-dried in water confirmed this 
hypothesis (data not shown). Complexation of QPa with sCT resulted in the disappearance of 
this peak and the small endotherms in the free sCT samples between 100-150oC, suggesting the 
presence of an interaction between QPa and sCT.  However, the multiple endotherms in the sCT 
and QPa samples between 225-250oC were still present in the complex sample. This suggests 
possible degradation of QPa and/or denaturation of sCT in the complex at a high temperature. 
In Fig 2C, sCT as received from the commercial supplier had a different thermal profile 
compared to the free sCT freeze-dried in acetate or Tris buffer. The differences observed may 
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suggest that there is an interaction between sCT and the buffer. This may explain the lack of 
stability in Tris compared to acetate buffer, which was shown in our result (section 3.1.2 and 
3.1.3) as well as others [20]. 
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Figure 2. DSC profile of (A) Freeze dried QPa, sCT and QPa:sCT complex (2:1mgmL−1) in acetate 
buffer. (B) Freeze dried QPa, sCT and QPa:sCT complex (2:1mgmL−1) in Tris buffer. (C)  freeze-dried 
sCT in acetate/ Tris buffer or as received.  
 
3.1.2. PCS, zeta potential and UV spectroscopy 
Samples were analysed for their hydrodynamic size, PDI, zeta potential and UV 
absorbance at day 0 and / or day 1 and at day 7 after preparation (Table 1). Samples were 
deemed stable at a gross level if absorbance readings remained below an O.D. value of 0.0-0.035 
[20]. sCT samples were stable at day 0, but by day 7 absorbance values had risen above 0.035 in 
both buffers. This was particularly marked for samples at pH 7.4 (A=0.269) compared to pH 5 
(A=0.044) suggesting that sCT was less stable at pH 7.4. The absorbance values for QPa alone 
were always above 0.035 as they were not completely clear. This meant that complex samples 
were also above 0.035. Again, however, samples appeared more stable at pH 5 than pH 7.4, 
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given the smaller changes in absorbance at day 7; absorbance increased from 0.054 to 0.071 and 
from 0.053 to 0.253 at pH 5 and 7.4, respectively (Table 1). The precipitation observed for both 
sCT and the complex at pH 7.4 at day 7 would suggest that the complex became unstable at this 
pH, although precipitation from the complex appeared to be less than from free sCT.  It would 
have been expected that if the sCT and QPa were not interacting with each other, two distinct 
size populations would be present in the complex samples which would be indicated by higher 
size and PDI values and multiple peaks in the size distribution graph. However, all complex 
samples over 7 days had diameter and PDI values of less than 230 nm and 0.3 respectively 
(Table 1). In addition, one single peak was obtained in the size distribution graphs (Fig 2A, B), 
suggesting that complexation between sCT and QPa led to formation of compact nano-
aggregates with relatively narrow size distribution at either pH. This suggests the absence of free 
sCT in the complexes, consistent with previous SEC-HPLC data from insulin-QPa complexes 
[11, 12]. Diameters and PDI values for sCT-QPa complexes were comparable to those of QPa, 
but differed markedly from those of sCT. Free sCT had a substantially higher hydrodynamic size 
ranging from 458nm to 2µm with a PDI of 1, indicating the presence of particulates of a wide 
diameter range.  
 
Table 1. Size, zeta potential and absorbance of sCT, sCT-QPa in pH 5.0 or Tris buffers  
 
 Day Hydrodynamic 
diameter (nm) 
 PDI Zeta Potential 
(mV) 
Absorbance 
(350 nm) 
     pH 5.0 
sCT 
       
       0 
 
      458 (141) 
 
0.527 (0.093) 
 
39.1 (2.54) 
 
0.000 
 7 2471 (934) 1.000 (0.000) 20.8 (2.70) 0.044 
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QPa  0 226 (2) 0.201 (0.015) 52.5 (0.92) 0.060 
  7 169 (4) 0.262 (0.003) 52.7 (1.17) 0.086 
sCT-QPa  0 226 (7) 0.232 (0.029) 56.6 (0.88) 0.054 
  1 227 (4) 0.228 (0.039) n/a 0.059 
 7 226 (5) 0.209 (0.031) 52.1 (1.09) 0.071 
    pH 7.4      
sCT  0 1827 (1279) 0.763 (0.191) 17.9 (0.78) 0.004 
 7 1339 (190) 0.802 (0.148) 4.5 (0.26) 0.269 
QPa  0 204 (2) 0.227 (0.008) 44.0 (2.07) 0.045 
   7 128 (3) 0.177 (0.008) 40.7 (3.66) 0.066 
sCT-QPa         0 197 (4) 0.206 (0.019) 44.7 (0.71) 0.053 
 1 194 (4) 0.203 (0.014) n/a 0.056 
 7 225(18) 0.293 (0.044) 49.6 (2.00) 0.253 
N= 3 ± SD for each parameter 
All samples had positive zeta potentials ranging from +21 mV to +50 mV, apart from 
free sCT at pH 7.4 at day 7 (Table 1). However, zeta potential values for sCT-QPa complexes 
were much higher than those of free sCT, but were similar to those of QPa alone. The zeta 
potential graphs of complexes in both pH 5 and pH7.4 buffers showed a single peak appearing at 
+57 mV and + 45mV respectively (Fig 3C, D), and these values were relatively constant after 7 
days (Table 1). 
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Fig. 3. Size distribution complexes at day 0 at pH 5.0 (A), and pH 7.4 (B). Zeta potential 
distribution of complexes at day 0 at pH 5.0 (C), and pH 7.4 (D) (triplicate samples).  
 
 
 
 
 
3.1.2. Intrinsic tyrosine fluorescence 
Intrinsic tyrosine fluorescence was measured in order to further assess stability of sCT in 
the complexes. The emission maxima wavelength should not change over time as it is intrinsic to 
tyrosine unless aggregation or fibril formation occurs.  Stable sCT samples should not lose/gain 
less than 6 % of their peak intensity between days 1 and 7 [24]. There was little change in 
λemission and peak intensities for most of the samples over the period (Table 2). Both the sCT-QPa 
(pH 5.0) complexes and sCT alone (pH 5.0) remained stable and peak intensities only altered by 
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2.6 % and 1.8 %, respectively. However the intensity of the sCT-QPa complexes (pH 5.0) fell by 
6.5 % and the sCT (pH 7.4) fell by 46.6 % at day 7. This would suggest that sCT is more stable 
at pH 5 than pH 7.4 and that complexation has a stabilizing effect on sCT at pH 5.0. QPa 
samples had negligible emission changes (data not shown). 
3.1.3 Nile red fluorescence 
sCT samples spiked with Nile red were considered stable if they had emission λmax values 
> 630 nm [20]. Small changes in intensity were considered to be due to fluctuations in 
temperature and binding of Nile red to sample containers. Nile red has an emission maximum of 
645 nm and the fall in maximum to 620-631 nm is a blue shift [20]. In contrast to tyrosine 
fluorescence, all Nile red spiked samples underwent shifts in emission λmax (Table 3). Free sCT 
samples displayed very little fluorescence (Table 3) as did Nile red alone in both buffers (data 
not shown). QPa itself also underwent a blue shift in the λmax, while sCT-QPa complexes (pH 5.0 
and 7.4) also exhibited blue shifts (Table 3). Given the shift in emission λmax of the complexes to 
below 630 nm it would appear that they were less stable than sCT alone. However this greater 
shift may be due to the combined effect of QPa and sCT interaction with Nile red. Therefore 
shifts in λmax may not be reliable indictors of stability with PEC samples. 
 
Table 2. Tyrosine fluorescence measurements of sCT and QPa, sCT complexes in pH 5.0 and 
pH 7.4 buffers (triplicate samples). 
 
            pH 5.0 Day Emission λmax,(nm) 
Intensity at 
maximum 
sCT  0 307 503 
 1 305 513 
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 7 305 504 
sCT-QPa 0 306 486 
 1 306 516 
 7 306 503 
 
pH 7.4 Day Emission λmax,(nm) 
Intensity at 
maximum 
sCT 0 303 443 
 1 304 434 
 7 306 232 
sCT-QPa 0 305 478 
 1 304 513 
 7 305 480 
 
 
Table 3. Fluorescence of Nile red (1 µM)-spiked sCT, QPa and sCT-QPa QPa complexes and in 
pH 5.0 and pH 7.4 buffers. 
 
pH 5.0  Day Emission λmax, (nm)  Intensity at maximum 
sCT 0 630 2 
 1 637 1.5 
 7 637 1.8 
QPa 0 631 232 
 1 632 203 
 7 632 144 
sCT-QPa 0 626 172 
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 1 626 165 
 7 626 164 
 
pH7.4 Day Emission λmax,  nm Intensity at maximum 
sCT 0 640 3.3 
 1 637 1.9 
 7 641 3.7 
QPa 0 626 196 
 1 628 171 
 7 627 172 
Complex 0 620 181 
 1 620 173 
 7 620 175 
3.1.4. TEM 
sCT did not form any discernable structures in either buffer when analysed using TEM 
(data not shown). The diameters of the sCT-QPa complexes at the two different pH values were 
approximately 120nm and the morphology of both complexes was similar; both appeared to be 
vesicular structures with aqueous cores (Fig. 4). The thickness of the vesicle was around 22nm, 
thicker than the typically reported bilayer membrane thickness of 11nm [24], indicating the 
membrane might consist of more than one bilayer. 
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Fig. 4. Negatively-stained TEM images of freshly-prepared sCT-QPa complexes (2:1 mg mL−1) 
in pH 5 buffer (A) or pH 7.4 buffer (B). Scale bar = 200 nm.  
 
3.2. Intracellular cAMP induced by sCT and sCT-QPa on T47D cells  
Intracellular cAMP activities in T47D cells were monitored to determine the bioactivity 
of sCT in freshly prepared complexes. Samples increased the intracellular cAMP in a 
concentration-dependent manner (Fig. 5A). Complexes in both buffers as well as free sCT were 
bioactive and maximal efficacy was achieved by each of the three groups. The EC50 values were 
(nM):  free sCT (0.73 ± 0.1), sCT-QPa, pH 7.4 (3.3 ± 0.1) and sCT-QPa at pH 5.0 (7.9 ± 0.1). 
Although the EC50 values suggested that the presence of QPa in the complexes at pH 7.4 and pH 
5.0 caused reductions in respective potency compared to free sCT, these nM values were still 
very acceptable. The sCT bioactivity of the freshly prepared samples at day 0 and at day 7 
following storage at room temperature in the dark was also determined (Fig 5B). Irrespective of 
the buffers used, free sCT was completely degraded at day 7, but there was still significant 
bioactivity in the complexes stored for 7 days. 
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Fig. 5.  A.  Concentration-response curves for sCT and sCT-QPa stimulation of cAMP 
production in T47D cells. sCT (○), sCT-QPa, pH 7.4 (□), sCT-QPa, pH 5.0 (▲). B. cAMP 
production by sCT and sCT-QPa complexes at pH 7.4 and pH5.0 on Day 0 and Day 7 on T47D 
cells. The concentration of sCT was 10µM in each preparation. (N=3 in each case).     
 
 
3.3. Intestinal enzyme metabolism 
Freshly prepared free sCT and sCT-containing complexes were incubated with three 
intestinal enzymes and the intracellular cAMP activities in T47D cells were determined. Free 
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sCT was rapidly degraded by chymotrypsin, elastase and trypsin. There was only 3% activity 
remaining in the free sCT when exposed to all three enzymes combined at 30 min (Fig 6). At 
both pH values, the sCT in the complexes was significantly protected from degradation by the 
enzymes.   
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Figure 6: Degradation profiles of sCT, sCT-QPa (pH 5.0) and sCT-QPa (pH 7.4) when 
incubated with three intestinal enzymes. Samples were applied onto T47D cells and cyclic AMP 
measured. sCT (○), sCT-QPa, pH 7.4 (    ), sCT-QPa, pH 5.0 (+). Curve fitting was based on first 
order kinetics (N=3 in each case).  
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Fig. 7 Comparison of degradation rates of sCT, sCT-QPa (pH 5.0) and sCT-QPa (pH 7.4) in the 
presence of serine proteases, as determined by cyclic AMP measurements in T47D cells. 
 
63.0 ± 0.1%, 57.0 ± 0.1% and 41.9 ± 0.02% bioactivity remained following sCT-QPa exposure 
to chymotrypsin, elastase and trypsin respectively for 90 min, pooled data at both pH values.  
QPa presence in both formulations reduced the degradation rate of sCT by 5-fold when all three 
enzymes were combined compared to free sCT (Fig 7) (p <0.005).  
 
3.4. Hypocalcaemia induced by sCT-QPa complexes in rats 
The biological effects of sCT-QPa complexes at pH 5.0 and pH 7.4 were evaluated by 
induction of hypocalcaemic response in rats following i.v. and i.j. administration. At sCT 
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equivalent doses following i.v. administration, the total percentage calcium decrease induced by 
sCT (pH 5.0) and sCT-QPa (pH 5.0) were similar, 23.1 ± 2.3% and 22.9 ± 3.8% at 120 min 
respectively (Fig. 8A). sCT (pH 7.4) and sCT-QPa (pH 7.4) induced decreases of  30.0 ± 2%  
and  29.3 ± 1.7% respectively over the same period. There were no differences between any of 
the sCT preparations.  QPa (pH 5.0 and 7.4) was without effect over the period following i.v. 
administration.  A very similar set of data was obtained following i.j. administration (Fig. 8B).  
The sCT-QPa complexes were bioactive in vivo with no loss of activity compared to free sCT. 
Intestinally instilled complexes retained the capacity to cross the epithelium.   
 
 
Fig.8. A. Plasma calcium levels in rat serum after i.v. administration of QPa, pH 5.0 (Δ), QPa, 
pH 7.4 (♦),  sCT, pH 5.0 (●), sCT, pH 7.4 (x), sCT-QPa, pH 5.0 (□), and sCT-QPa, pH 7.4 (▼).  
Mean ± SEM (n = 3).  B.i.j administration: groups and symbols as in A. (N = 3-4).   
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4. Discussion 
There are four commercially available formulations of sCT; the recommended dose for 
the daily nasal spray to treat post-menopausal osteoporosis is 200 I.U, while 100 I. U. are 
administered every other day for injections. sCT is normally formulated in acidic media 
consisting of acetate, hydrochloric acid or citric acid buffers, as sCT is more stable in acid pH 
than at pH 7.4 [25]. Since the isoelectric point of sCT is 10.2, it will be positively-charged at 
acidic and physiological pH values [26]. We looked at the ability of the cationic amphiphilic 
polyelectrolyte (QPa) to complex with sCT at pH 5.0 and 7.4 and assessed the impact of the 
polymer on sCT’s physical stability, resistance in vitro enzymatic degradation and in vitro and in 
vivo bioactivity. We did not expect complexation to occur easily in view of the likely potential 
for electrostatic repulsion. 
Polyamines are effective non-cytotoxic permeation enhancers across intestinal epithelia 
and they can open epithelial tight junctions in vitro [27].  For example, spermine formulated in 
polyacrylic acid polyelectrolyte complexes improved the oral absorption of sCT in rats following 
intra-duodenal administration [28]. It is possible that QPa may also act as an epithelial 
permeation enhancer and this may be of benefit in addition to peptidase inhibition.  Initial studies 
suggest that it also reversibly opens tight junctions in Caco-2 monolayers (unpublished data). 
We have previously illustrated the potential use of amphiphilic polyamines based on PAA for 
oral insulin delivery [11, 12]. The attachment of palmitoyl chains and the addition of quaternary 
ammonium moieties resulted in an 11-fold reduction in cytotoxicity of QPa compared to its 
parent molecule (PAA),  Although sCT is positively charged, complexation was still achieved 
with QPa in the current study, resulting in a narrow particle size distribution with a 
hydrodynamic diameter  of approximately 200nm. Unlike other polyelectrolyte complexes, 
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which require centrifugation to obtain the nano-complexes, freshly prepared sCT-QPa complexes 
were clear in appearance, confirmed by the low absorbance UV reading and the absence of 
pellets after centrifugation. The differences observed between the DSC thermal profiles of free 
sCT and complexes in both pHs suggesting the presence of physical-chemical interaction 
between sCT and QPa, which correlated well with other polyelectrolyte-protein complexes 
[11,19]. The assessment of the physical stability of the complex was based on data from the 
combination of size and zeta potential measurements, turbidity, as well as intrinsic and extrinsic 
fluorescence.  Overall, QPa complexation had a positive effect on the physical stability of sCT. 
Unstable formulations would have resulted in an increase in particle size, turbidity and peptide 
aggregation. While free sCT was more physically stable for longer periods at pH 5.0 than pH 7.4 
according to the tyrosine fluorescence study, the in vitro bioassay suggested little difference at 
the level of function where both very equally efficacious at Day 0 and inefficacious at Day 7. 
Although sCT-QPa (pH 7.4) complexes showed some signs of instability at 7 days, the changes 
detected by these studies were considerably less than the deterioration in free sCT (pH 7.4) over 
the same period.   
Nile red can detect hydrophobic micro-domains in aqueous solutions formed by 
amphiphilic polymers [29]. The blue shift in the maximum emission wavelength observed with 
QPa correlates with the results with alkylated poly(L-lysine) citramide [29]. Thus, it partitions 
from the aqueous environment into the hydrophobic domains formed by the palmitoyl grafts on 
QPa. Importantly, a similar blue shift was also observed in free sCT (pH 5. 0), indicating the 
presence of hydrophobic domains on the peptide. Finally, when sCT was complexed with QPa, 
the further reduction in the maximum emission wavelength suggests that likely changes in the 
conformation of the complex exposed additional hydrophobic surfaces for dye binding. From 
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TEM images, it would appear that the polymer and sCT interact and alter the conformation of 
both. QPa normally forms discrete, dense nanoparticles, either alone or when complexed with 
insulin [10-12]. When complexed with sCT however, there was an unusual alteration in the 
conformation, resulting in a bilayered vesicular structure. In sum, sCT seems to undergo 
unfolding in the presence of QPa, which results in exposure of hydrophobic domains. Assuming 
that these domains intercalate between the palmitoyl chains of QPa, such interactions may lead 
to increased backbone flexibility and the subsequent production of liposome-like bilayer vesicles 
[30, 31].  
Amphiphilic polyelectrolytes for peptide and protein delivery have not been widely 
studied to date. Unlike complexation between proteins and polyelectrolytes based on electrostatic 
interaction, association of proteins with amphiphilic polyelectrolytes in water can be affected by 
non-covalent hydrophobic Van der Waals associations and hydrogen bonds. Even though QPa 
and sCT are both positively charged, complexation still took place.  Pockets of anionic charges 
on the surface of sCT may interact with QPa, as shown for other peptide-polymer complexes 
[32].  Still, sCT-QPa PEC had consistent and narrowly distributed zeta potentials similar to QPa 
alone, inferring that the predominant interaction was indeed due to hydrophobic associations or 
hydrogen bonds.   Others have successfully used co-polymers consisting of a hydrophobic 
polystyrene backbone grafted with poly-N-isopropylacrylamide (PNIPAAm) and 
polyvinylamine (PVAm) for sCT delivery [9]. The presence of non-ionic PNIPAAm and cationic 
PVAm in the nanocomplexes resulted in increased oral biovailability, which may have been due 
to hydrogen bonding between sCT and macro-monomer chains.  Similarly, formation of 
complexes composed of serum albumin and negatively-charged polyacrylates modified with 
alkyl chains has been achieved [33]. The complexation was dependent in part on the number of 
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alkyl chains, implying that hydrophobic association is indeed an especially important parameter 
in the complexation process when amphiphilic polyelectrolytes and the protein have the same 
overall surface charge.  
Use of conventional delivery systems including poly(D,L lactide-co-glycolide) 
microparticles might lead to reduction of sCT bioactivity and even induce immunogenicity due 
to chemical modifications such as acylation and also pH changes in the particulates [34]. 
Therefore, it is important to assess the bioactivity of sCT in the QPa complexes. There is 
excellent correlation between the in vitro bioassay and HPLC analysis for sCT and polymeric 
derivatives [22] and hence in this study, we relied on determination of the bioactivity of sCT on 
T47D cells, since HPLC does not detect loss of function. At both pH values, the sCT-QPa 
complexes had the same excellent efficacy and just a slight loss in potency compared to free 
sCT. sCT adopts a random coil structure, but has a relatively undeveloped secondary structure 
and no tertiary conformation [35], but despite likely changes in secondary conformation in the 
nanocomplex, it is still able to maintain its in vitro biological activity.  The sCT bioactivities 
were also evaluated on the day 7 formulations, which were kept in the dark at room temperature. 
Free sCT was completely degraded by day 7, while both complexes maintained significantly 
higher bioactivity than free sCT at both pH 5.0 and pH 7.4. In aqueous solutions sCT normally 
undergoes rapid degradation including disulphide breakage and subsequent trisulphide bond 
formation, as well as dimerization via covalent bond and backbone hydrolysis [36].  
Complexation of sCT with QPa reduced the degradation process and at least 40% of the activity 
was retained after 7 days. Although the physical stability studies indicated that day 7 complexes 
at pH 7.4 were less stable than those at pH 5.0, it was somewhat surprising to find that both 
complexes retained similar in vitro sCT bioactivity. The secondary structure of sCT is based on 
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an α-helix and β-sheet [37]. Their presence in sCT may in part promote fibril formation and 
aggregation in aqueous solutions, ultimately leading to physical instability [34, 36], although this 
is thought to not to occur nearly as readily with sCT as for human CT. Despite this possibility, 
the sCT in the complex formed in either pH buffer was still able to interact with calcitonin 
receptors to elicit the biological response.  
Proteins and peptides undergo extensive enzymatic degradation in the intestine, serum 
and liver . Complexation between sCT and QPa has resulted in significant protection of sCT 
from the major endopeptidases at concentrations present in the small intestine. When sCT was 
conjugated to either linear PEG or to a novel comb-shaped Poly(PEG)methacrylate polymer, 
almost identical protection was noted as in the current study [22]. Most likely, the complexed 
QPa shielded the sCT and this steric hindrance mechanism (similar to the umbrella-like effect 
postulated for poly(PEG)methacrylate)  protected sCT from peptidase attack. It would not be 
correct however, to assume that generalizations can be made in respect of polymer protection, 
since complexation between QPa and insulin resulted in increased peptide degradation by 
chymotrypsin compared to that seen with free insulin [12]. This demonstrates that whether 
amphiphilic polyelectrolytes can protect proteins against enzymatic degradation is largely 
dependent on the protein, its surface charge and its secondary and tertiary structure. Insulin is a 
globular protein with a tertiary conformation and complexation resulted in the unfolding of the 
protein exposing the chymotrypsin target sites. It is possible that absence of tertiary 
conformation in sCT resulted in minimal unfolding, and therefore the shielding effect of QPa 
resulted in protection against peptidases. In vivo biological efficacy of sCT-QPa complexes were 
assessed in rats and irrespective of the type of buffers used, both formulations had similar 
hypocalcaemic effects compared to free sCT, consistent with our in vitro bioactivity assays. 
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Intra-jejunal administration revealed that the complexes retained bioactivity, although we did not 
ascertain whether they remain intact during epithelial transport.  This is likely however, since the 
complexes protected sCT in a range of peptidase containing buffers over significant time periods.  
Future work will further investigate the potential of these complexes by administering these 
complexes by single pass rat intestinal perfusion and ultimately by oral gavage of coated solid-
dose formulations. 
 
5. Conclusions 
Despite similar overall surface charges, sCT-QPa nano-complexes were spontaneously 
produced by mixing two aqueous solutions at room temperature without the need for surfactant 
stabilizers, organic solvents or sonication. Unlike complexation between protein and 
polyelectrolyte of oppositely charges relying primarily on electrostatic interaction, it is likely that 
the predominant interaction of QPa, sCT was due to hydrophobic associations of palmitoyl 
chains grafted onto PAA. The complexation resulted in the production of nano-complexes in the 
region of 200nm which were able to maintain stability physical and biological stability compared 
to free sCT in either pH 5.0 or 7.4 buffers. The ability of QPa to protect sCT against intestinal 
enzymatic degradation and to achieve similar in vivo hypocalcaemic responses as for free sCT 
following i.j. administration warrant further investigation to determine its potential as an oral 
peptide delivery system. 
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